EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Biological Evaluation of a Novel Compound with Predicted EZH2 and EED Binding Against Human Malignant Melanoma Cells

Sergei Gorbunov iD, Sotiris Kyriakou iD, Ioannis Anestopoulos iD, Shahzaib Khoso, Marcello Manfredi iD, Rodrigo Franco iD, Aglaia Pappa iD, Mihalis I Panayiotidis iD

International Journal of Molecular Sciences · 13.03.2026 · 27 (6) · 2647

DOI: 10.3390/ijms27062647 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 13.03.2026. Verfasst von Sergei Gorbunov und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Genetics, Therapeutics and Ultrastructural Pathology, The Cyprus Institute of Neurology and Genetics, Nicosia 2371, Cyprus. Hauptthemen laut MEDLINE: Enhancer of Zeste Homolog 2 Protein, Melanoma, Polycomb Repressive Complex 2, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Competitiveness, Entrepreneurship and Innovation, Greece and the European Union, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Enhancer of Zeste Homolog 2 (EZH2), the catalytic subunit of Polycomb Repressive Complex 2 (PRC2), mediates histone H3 lysine 27 trimethylation (H3K27me3), an epigenetic modification associated with transcriptional repression. EZH2 inhibitors (EZH2is) gained attention after the first-in-class drug Tazemetostat received FDA approval for treating epithelioid sarcoma. Preclinical studies suggest that EZH2is could be effective against melanoma, but their general inability to cross the blood–brain barrier (BBB), among others, limits the treatment of secondary brain metastases. Based on these limitations, we designed SG-8, a novel compound derived from TDI-6118 (a known brain-penetrant EZH2i). In silico docking predicted that SG-8 may exhibit high affinity for EZH2 as well as for another PRC2 subunit, Embryonic Ectoderm Development (EED). In addition, in vitro PAMPA assays suggested passive BBB permeability of SG-8. In cell-based assays, SG-8 and the structurally related EZH2i PF-06726304 displayed lower cytotoxicity than Tazemetostat in both primary (A375) and metastatic (Colo-679) human melanoma cells. Western blot analysis showed that SG-8 and PF-06726304 markedly reduced EED protein levels and, to a lesser extent, EZH2 levels, without affecting total H3K27me3, consistent with preserved canonical PRC2 activity. Instead, treatment with both compounds—most prominently SG-8—was associated with reduced phosphorylation levels of EZH2 (Ser21) and its upstream regulator Akt (Ser473), suggesting that modulation of the Akt–EZH2 signaling axis may at least partially contribute to their anti-melanoma activity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Enhancer of Zeste Homolog 2 ProteinMelanomaPolycomb Repressive Complex 2Antineoplastic AgentsHumansCell Line, TumorMolecular Docking SimulationProtein BindingBlood-Brain BarrierBenzamidesBiphenyl CompoundsMorpholinesPyridones

Stichwörter der Autor:innen

EEDEZH2H3K27 methylationPRC2Tazemetostatblood–brain barrierhistone methyltransferasemalignant melanoma

Substanzen

Enhancer of Zeste Homolog 2 ProteinEZH2 protein, humanPolycomb Repressive Complex 2EED protein, humanAntineoplastic AgentstazemetostatBenzamidesBiphenyl CompoundsMorpholinesPyridones

Autor:innen und Institutionen

  • Department of Cancer Genetics, Therapeutics and Ultrastructural Pathology, The Cyprus Institute of Neurology and Genetics, Nicosia 2371, Cyprus.
  • Department of Translational Medicine, Center for Translational Research on Autoimmune and Allergic Diseases, University of Piemonte Orientale, 28100 Novara, Italy.
  • Institute for Molecular and Translational Cardiology (IMTC), IRCCS Policlinico San Donato, 20097 Milan, Italy.
  • Redox Biology Centre, University of Nebraska-Lincoln, Lincoln, NE 68583, USA.
  • Department of Veterinary Medicine and Biomedical Sciences, University of Nebraska-Lincoln, Lincoln, NE 68583, USA.
  • Department of Molecular Biology and Genetics, Democritus University of Thrace, 68100 Alexandroupolis, Greece.

ORCID-Profile: Sergei Gorbunov, Sotiris Kyriakou, Ioannis Anestopoulos, Marcello Manfredi, Rodrigo Franco, Aglaia Pappa, Mihalis I Panayiotidis

Förderung

  • Competitiveness, Entrepreneurship and Innovation
  • Greece and the European Union
  • Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus

Zitieren

APA

Gorbunov, S., Kyriakou, S., Anestopoulos, I., Khoso, S., Manfredi, M., Franco, R., Pappa, A., & Panayiotidis, M. I. (2026). Biological Evaluation of a Novel Compound with Predicted EZH2 and EED Binding Against Human Malignant Melanoma Cells. International Journal of Molecular Sciences, 27(6), 2647. https://doi.org/10.3390/ijms27062647

Vancouver

Gorbunov S, Kyriakou S, Anestopoulos I, Khoso S, Manfredi M, Franco R, et al. Biological Evaluation of a Novel Compound with Predicted EZH2 and EED Binding Against Human Malignant Melanoma Cells. International Journal of Molecular Sciences. 2026;27(6):2647. doi:10.3390/ijms27062647

BibTeX
@article{Gorbunov2026,
  author = {Gorbunov, Sergei and Kyriakou, Sotiris and Anestopoulos, Ioannis and Khoso, Shahzaib and Manfredi, Marcello and Franco, Rodrigo and Pappa, Aglaia and Panayiotidis, Mihalis I},
  title = {Biological Evaluation of a Novel Compound with Predicted EZH2 and EED Binding Against Human Malignant Melanoma Cells},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {6},
  pages = {2647},
  doi = {10.3390/ijms27062647}
}
Kostenlos starten →